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The function of tumor suppressor VHL is compromised in the vast majority of clear cell
renal cell carcinoma, and its mutations or loss of expression was causal for this disease.
pVHL was found to be a substrate recognition subunit of an E3 ubiquitin ligase, and most
of the tumor-derived mutations disrupt this function. pVHL was found to bind to the alpha
subunits of hypoxia-inducible factor (HIF) and promote their ubiquitination and proteaso-
mal degradation. Proline hydroxylation on key sites of HIFα provides the binding signal for
pVHL E3 ligase complex. Beside HIFα, several other VHL targets have been identiﬁed,
including activated epidermal growth factor receptor (EGFR), RNA polymerase II subunits
RPB1 and hsRPB7, atypical protein kinase C (PKC), Sprouty2, β-adrenergic receptor II, and
Myb-binding protein p160. HIFα is the most well studied substrate and has been proven
to be critical for pVHL’s tumor suppressor function, but the activated EGFR and PKC and
other pVHL substrates might also be important for tumor growth and drug response.Their
regulations by pVHL and their relevance to signaling and cancer are discussed.
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Loss of function of the tumor suppressor gene VHL is causal
in the pathogenesis of clear cell renal cell carcinoma (ccRCC).
The vast majority (70–80%) of sporadic RCCs are pathologically
characterized as ccRCC. Among them, approximately 70% harbor
biallelic inactivation ofVHL throughmutation,deletion,or hyper-
methylation of promoter (Kaelin, 2002; Linehan and Zbar, 2004).
Inherited germline mutations in VHL predispose these patients
to bilateral kidney cancer earlier than the sporadic kidney cancer
patients, since the loss of the remaining wild type allele occurs
more readily than the loss of two alleles. The protein product
of the VHL tumor suppressor gene, pVHL, is found to be the
substrate recognition unit of an E3 ubiquitin ligase complex that
contains Cullin 2 (Cul2), Elongin B and C, and Rbx1 (Kamura
et al., 1999a,b). Interestingly, tumor-derived point mutations were
found to cluster around substrate recognizing (β domain) or the
Elongin C-binding (α domain) sites (Stebbins et al., 1999), stress-
ing the importance of ubiquitin ligase activity to pVHL’s tumor
suppressor function. This complex targets the α subunits of the
heterodimeric transcription factor hypoxia-inducible factor (HIF)
for ubiquitination and proteasome-mediated degradation (Ohh
et al., 2000). In addition to being a part of an E3 ubiquitin ligase
complex, pVHL also regulates other HIF-independent biological
processes such as inhibition of NF-κB activity (Yang et al., 2007),
maintenance of chromosome stability (Thoma et al., 2009), and
promoting cilia production (Schraml et al., 2009), which will not
be reviewed in this article.
The best-characterized substrates for pVHL-containing ubiq-
uitin ligase are the alpha subunits of the HIF transcription factor.
HIF contains two subunits: the oxygen-sensitive alpha subunits
(HIF1α, HIF2α, and HIF3α, for the simplicity they will be collec-
tively calledHIFα) and the constitutively expressedHIF1β subunit
[also called the aryl hydrocarbon nuclear translocator (ARNT);
Semenza, 2007]. pVHL recognizes the HIFα only after they are
hydroxylated on either of two critical prolyl residues by members
of the EglN family (also called PHDs or HPHs; Epstein et al., 2001;
Ivan et al., 2001, 2002; Jaakkola et al., 2001). These enzymes require
molecular oxygen, Fe(II) and 2-oxoglutarate for activity. Under
normal oxygen tension (normoxia), the critical proline residues
on HIFα subunits are hydoxylated (P402 and 564 on HIF1α),
recognized by pVHL, poly-ubiquitinated, and destroyed by the
proteasome.When the oxygen is deprived (hypoxia) by physiolog-
ical or pathological conditions, theHIFα subunitswill be produced
but cannot be prolyl hydroxylated. They escape the recognition by
pVHL, accumulate, and hetero-dimerize with HIF1β. The het-
erodimer enters nucleus, recruit transcriptional coactivator com-
plexes (Arany et al., 1996; Ema et al., 1999), and regulate the
expression of (inducing or suppressing) hundreds of target genes
by binding to the hypoxia-response element (HRE; Semenza, 2003;
Figure 1). Activation of HIF leads to physiological adaptations
to the deprivation of oxygen: a metabolic shift to anaerobic gly-
colysis, increased secretion of pro-angiogenesis factors that leads
to growth of blood vessels and increased blood supply, remod-
eling of the extracellular matrix, and resistance to apoptosis and
increased mobility. In VHL-defective ccRCC tumors, enhanced
angiogenesis and constitutive activation of the HIF pathway are
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FIGURE 1 |The regulation of the HIFα by pVHL-containing E3 ubiquitin
ligase complex. During normoxia, HIFα is produced and prolyl hydroxylated
by PHD1–3. The hydroxyproline provides a binding signal for pVHL, which
leads to efﬁcient ubiquitylation and proteasomal degradation of HIFα
protein. During hypoxia, HIFα is not prolyl hydroxylated and escapes pVHL
recognition. HIFα accumulates and forms complex with HIF1β, goes into
nucleus and turns on a transcriptional program to cope with the short-term
and long-term effects of oxygen deprivation.
prominent features even when the oxygen supply is not limited.
In the xenograft models of ccRCC, constitutive HIF activation
was both sufﬁcient (Kondo et al., 2002) and necessary for tumor
growth (Kondo et al., 2003; Zimmer et al., 2004). In the clinic
trials, drugs that block the activities of the receptors for vascular
endothelial growth factor (VEGF), a critical HIF target gene, pro-
duced clear and positive, albeit often transient, clinical outcomes
in kidney cancer patients (Rini, 2005).
Interestingly, although HIF2α is a potent oncogene, the acti-
vations of HIF targets are not necessarily all tumor-promoting
events.HIF-dependent activation of REDD1 suppressedmTORC1
(Kucejova et al., 2011), andHIF-dependent activation of JARID1C
decreased the overall level of the trimethylated histone H3 lysine 4
(H3K4Me3;Niu et al., 2012). Both were tumor-suppressive events,
and kidney tumors found clever ways to inactivate them (Dalgliesh
et al., 2010; Kucejova et al., 2011). Further careful analysis of how
HIF targets contribute to kidney tumor growth and maintenance
might yield new ways to treat kidney cancer.
ACTIVATED EPIDERMAL GROWTH FACTOR RECEPTOR
It is known thatHIF can enhance epidermal growth factor receptor
(EGFR) activity to promote tumor growth (de Paulsen et al., 2001;
Franovic et al., 2007). InVHL-defective ccRCCcells, the expression
of transforming growth factor-α (TGF-α), an agonist to EGFR, is
induced by HIF2α. This stimulates cell proliferation through an
autocrine loop (de Paulsen et al., 2001). At the same time, con-
stitutively active HIF2α also increases the translational efﬁciency
of EGFR mRNA (Franovic et al., 2007). Increased EGFR expres-
sion and elevated TGF-α work together to promote autonomous
growth (cellular growth in the absence of stimulating growth fac-
tors),which is a hallmark of cancer. Stable suppression of EGFR by
shRNAs prevents serum-free growth ofVHL-defective ccRCC cells
in vitro, and retards the tumor growth of these cells for extended
periods in vivo without affecting HIF2α functions (Smith et al.,
2005; Lee et al., 2008). This suggests that EGFR is critical for the
tumor growth of VHL-defective ccRCC cells and could be a good
therapeutic target in kidney cancer.
Epidermal growth factor receptor is implicated inmany human
cancers, as activating mutations of EGFR have been identi-
ﬁed in human glioblastoma, non-small cell lung carcinomas
(NSCLC), and colon cancer. Upon ligand binding, EGFR and its
family members homo- or hetero-dimerize, trans-phosphorylate
the c-terminal tyrosine residues. These phosphorylated residues
recruit signaling molecules, which activate downstream effec-
tors and elicit biological responses (Yarden and Sliwkowski,
2001). Ras/Raf/MEK/ERK and PI3K/PDK1/Akt1 are two major
downstream pathways of activated EGFR. Since they promote
both cellular proliferation and resistance to apoptosis (Jorissen
et al., 2003), failure to turn off the activated EGFR can drive
tumorigenesis.
Endocytosis and lysosome-mediated degradation is reported to
be the major mechanism to down-regulate the activated EGFR. By
binding to EGFR either directly through phosphorylated Y1045
(Levkowitz et al., 1999) or through its association with another
EGFR-interacting protein Grb2 (Waterman et al., 2002), the ubiq-
uitin ligase c-Cbl promotes its ubiquitination (Levkowitz et al.,
1998). c-Cbl promotes mono-ubiquitylation on multiple lysine
residues of EGFR, which is sufﬁcient for EGFR endocytosis and
degradation (Haglund et al., 2003a,b;Mosesson et al., 2003),How-
ever,mass-spectrometric and western blot analyses have suggested
that a fraction of activated EGFR is poly-ubiquitinated (Huang
et al., 2006; Umebayashi et al., 2008). Thus it is possible that other
E3 ubiquitin ligases add poly-ubiquitin to the activated EGFR to
promote its turnover.
Recently it was reported that pVHL was essential for the clear-
ance of activated EGFR (Wang et al., 2009) and the proposed
mechanism was that constitutively active HIF suppressed the
lysosomal-mediated degradation of the activated EGFR. Specif-
ically, Wang et al. suggested that HIF reduced the expression of
Rabaptin-5. As Rabaptin-5 was critical for Rab5-mediated endo-
some fusion, reduced expression of Rabaptin-5 led to delayed
EGFR sorting to the late endosome and lysosome, and this led
to longer half-lives of the activated EGFR. This explanation pre-
dicted that delayed turnover of activated EGFR in VHL-defective
ccRCC cells was due to high levels of HIF α subunits. However,
Zhou andYang (2011) found that the endogenousHIF was not the
only or major cause of delayed EGFR turnover in VHL-defective
ccRCCcells. Furthermore, they found that pVHL-mediated down-
regulation of the activated EGFR was mostly mediated by protea-
some instead of lysosome. In addition, loss of both c-Cbl andVHL
caused the activated EGFR to become completely stable during
the experiment, suggesting that these ubiquitin ligases collabo-
rated to down-regulate activatedEGFR. Finally it was reported that
pVHL promoted the poly-ubiquitination of the activated EGFR,
and this persisted in the absence of c-Cbl. Thus in ccRCC cells,
pVHL promotes the poly-ubiquitination of the activated EGFR
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FIGURE 2 | A model of how pVHL and c-Cbl promote the turnover of
the activated EGFR. After EGFR is activated by its agonist, it becomes
phosphorylated at multiple sites. c-Cbl promotes multi-mono-ubiquitylation
on the activated EGFR which leads to lysosome-mediated turnover, while
pVHL promotes polyubiquitination on the activated EGFR which leads to
proteasomal degradation.
and subsequent proteasomal degradation that is independent of
c-Cbl (Figure 2). Further study is needed to determine the relative
contributions of the HIF-dependent and HIF-independent mech-
anisms that pVHL uses to suppress activated EGFR. Nevertheless,
inVHL-defective ccRCC cells, the prolonged signaling of the acti-
vated EGFR, together with elevated TGF-α and EGFR protein
level, likely contributes to tumor growth. As the activated EGFR
that is phosphorylated at some sites displayed VHL-dependent
degradation (unpublished data), it is likely that pVHL-dependent
polyubiquitination of activated EGFR is not a phenomenon that
is unique to kidney cancer cells.
RNA POLYMERASE II SUBUNITS
Large subunit of RNA polymerase II (RPB1) is responsible for the
initiation and elongation of mRNA and its activity is regulated
through its c-terminal phosphorylation (Kuznetsova et al., 2003;
Table 1). Through bioinformatic analysis, Kuznetsova et al. (2003)
found that a fragment of RPB1 share some sequence similarity
with oxygen-dependent degradation domain (ODDD) of HIF1α.
In addition, RPB1 also contained an analogous LXXLAP sequence
that was found inHIF1α protein that was the site of prolyl hydrox-
ylation that mediated recognition by pVHL. In response to DNA
damage agents or UV radiation, RPB1 underwent hyperphospho-
rylation and then proline hydroxylation. This led to recognition by
pVHL-associated E3 ligase complex and its ubiquitination in PC12
cells. By testing the in vitro binding between RPB1 peptide and
radio-labeled pVHL, they showed that hydroxylated RPB1 Proline
1465 was the major site that mediated interaction with pVHL.
However, it remained to be determined whether hyperphosphory-
lation on RPB1 led to its proline hydroxylation. They also showed
that the amount of hyperphosphorylated, but not hypophospho-
rylated RPB1 correlates inversely with pVHL levels in PC12 cells.
These data suggests that pVHL binds to RPB1 through hydroxy-
lated proline, promotes the ubiquitination of RPB1, and reduces
hyperphosphorylated RPB1 levels in response to UV or DNA
damage agents in PC12 cells.
Surprisingly, when pVHL was re-expressed in two different
VHL-deﬁcient kidney cancer cell lines, pVHL increased the level of
RPB1 instead of decreasing it as expected (Mikhaylova et al., 2008).
Furthermore, overexpression of wild type RPB1, not the P1465A
mutant that cannot be hydroxylated, promoted tumor growth in
kidney cancer cells expressing wild type VHL. Since the P1465A
mutant RPB1 escapes VHL regulation, this is against the hypoth-
esis that loss of VHL regulation on RPB1 is a tumor-promoting
event. However, subsequent studies did reveal that RPB1 hydrox-
ylation was signiﬁcantly higher in kidney tumors compared to
normal control. Consistent with the ﬁnding that PHD1 (EglN2,
one of prolyl hydroxylases that modify HIFα) was the primary
hydroxylase thatmodiﬁes RPB1, levels of RPB1 hydroxylation cor-
related with levels of PHD1 in kidney cancer (Yi et al., 2010). Thus
the contribution of RPB1 hydroxylation and pVHL-dependent
ubiquitination tokidney cancer remainsunclear andawaits further
investigation.
In addition to RPB1, Na et al. discovered a novel pVHL-
interacting protein, human RNA polymerase II seventh subunit
(hsRPB7) by performing yeast two-hybrid screening froma kidney
cDNA library. hsRBP7 bound to the 54–113 amino acid regions of
pVHL, a part of VHL β-domain responsible for substrate recog-
nition (Na et al., 2003). Interestingly, two representative VHL
β-domain mutants (P86H and Y98H) showed decreased binding
to hsRPB7 compared to wild type. hsRBP7 underwent VHL-
dependent ubiquitination and proteasome-dependent degrada-
tion.As a functional readout,hsRPB7 can positively regulateVEGF
expression, an effect that was ameliorated by overexpressing VHL
in kidney cancer cells. However, in this paper, it was not clear
whether hydroxylation would play a role in hsRBP7’s degradation
by pVHL E3 ligase complex. It will also be critical to identify the
molecular mechanism by which hsRPB7 regulates the expression
of speciﬁc genes such as VEGF.
PROTEIN KINASE C
Protein kinase C (PKC) is a superfamily of phospholipid-activated
serine/threonine kinase.Activation of canonical PKC familymem-
bers by 12-O-tetradecanoylphorbol-l3-acetate (TPA) can lead to
various cellular responses, such as change of cell morphology and
increased cell proliferation (Hata et al., 1993; Table 1). Various
PKC family members were reported to bind to VHL, and this
led to their ubiquitination and degradation. Although PKCδ was
found to interact with the β domain of pVHL, its overall pro-
tein level was not affected by pVHL status (Iturrioz et al., 2006).
Instead it was PKCζII that was reported to be a pVHL substrate,
and its c-terminuswas important forVHL-dependent proteasomal
degradation (Iturrioz and Parker, 2007). While wild type pVHL
could promote the degradation of PKCζII efﬁciently, some tumor-
derived VHL mutants (such as Y98H, C162W, and R167W) failed
to do so.However, it remained unclearwhether PKCζII was a direct
substrate for pVHL complex, and whether proline hydroxylation
played a role in the turnover of PKCζII.
Protein kinase Cλ/4RA contains point mutations that render
it partially and constitutively active (Akimoto et al., 1996). The
active form of PKCλ bound to pVHL tighter than its wild type
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Table 1 | A brief description of the pVHL substrates and the types of cancer they are involved in.
Gene name Biological functions Types of cancer involved Reference
HIFα (HIF1, 2, and 3α) Mediate transcriptional adaptation to oxygen
deprivation by enhancing metabolic change,
migration, and angiogenesis
All types of cancer Semenza (2010)
EGFR (epidermal growth
factor receptor)
Activate Ras/Raf/MEK/ERK and PI3K/PDK1/Akt1
pathways; promote cell proliferation; and
resistance to apoptosis
All types of cancer Jorissen et al. (2003), Yarden and
Sliwkowski (2001)
RPB1 (large subunit of
RNA polymerase II)
The largest subunit of RNA polymerase II, the
polymerase responsible for synthesizing
messenger RNA in eukaryotes
Kidney cancer Yi et al. (2010)
RPB7 (RNA polymerase
II seventh subunit)
The seventh largest subunit of RNA polymerase II
that reportedly increases VEGF expression
Kidney cancer Na et al. (2003)
aPKC (atypical protein
kinase C)
Activates MAPK and upregulate VEGF expression
(PKCδ); phosphorylates MUC1 and potentiates
β-catenin signaling (PKCδ); increases cancer cell
migration (PKCδ); acts as endogenous inhibitors of
tight junction formation (PKCζII)
Breast cancer Pal et al. (1997), Ren et al. (2002),
Razorenova et al. (2011), Reno et al.
(2008), Parkinson et al. (2004)Colon cancer
Kidney cancer
Endometrial cancer
SPRY2 (sprouty2) Antagonizes the activated receptor tyrosine
kinases and downregulates angiogenesis
Breast cancer Lee et al. (2001), Lo et al. (2004),
Fong et al. (2006), McKie et al.
(2005), Sutterluty et al. (2007), Feng
et al. (2011)
Hepatocellular cancer
prostate cancer
Lung cancer
Colon cancer
β2AR (β-adrenergic
receptor II)
Mediate the catecholamine-induced activation of
adenylate cyclase through the action of G proteins.
involved in cardiovascular functions and apoptosis
Currently not known Rockman et al. (2002)
MYBBP1A (Myb-binding
protein p160)
May activate or repress transcription through
interactions with DNA-binding proteins
Head and neck squamous
cell carcinoma
Diaz et al. (2007),Tavner et al. (1998),
Acuna Sanhueza et al. (2012)
counterpart, and this led to its preferential ubiquitination byVHL
E3 ligase complex (Okuda et al., 2001).
Atypical PKCλ interacted withASIP/PAR-3 and PAR-6 andwas
important for the maintenance of the tight junctions and the cell
polarity in epithelial cells (Suzuki et al., 2001). In another epithe-
lial cell line HC11 PKCζII was critical to maintain the cells in
a non-differentiated state characterized by the absence of tight
junctions and cell overgrowth (Parkinson et al., 2004). Since pVHL
was reported to bind and degrade several PKC family members,
it was reasonable to hypothesize that pVHL can affect actin and
cytoskeletal organization, tight junction formation and cell polar-
ity, which were often found dysregulated in cancer cells. Further
study is needed to investigate the functional role of theVHL–PKCs
axis in kidney cancer.
SPROUTY2
Sprouty2 (SPRY2) is one of four mammalian sprouty family
members (SPRY1–4; Hacohen et al., 1998). Previous research
showed that SPRY family members negatively regulated the activ-
ities of receptor tyrosine kinase and reduced angiogenesis (Lee
et al., 2001; Table 1). Anderson et al. (2011) reported that
hypoxia increased SPRY2 protein levels in various cancer cells,
and it did so mainly through increased SPRY2 protein stability.
While knockdown of PHD1 or PHD3 increased SPRY2 pro-
tein levels, overexpression of all three PHD isoforms (PHD1,
2, and 3) decreased its protein levels. By mass spectrometry,
three potential prolyl hydroxylation sites were identiﬁed (P18,
144, and 160). Mutating these three Proline residues to Ala-
nine residues signiﬁcantly decreased the binding between SPRY2
and pVHL and produced more stable SPRY2 protein. Func-
tionally, since SPRY2 was reported to have anti-migratory and
anti-proliferative effect on cancer cell growth through inhibiting
ERK1/2 kinase pathway (Impagnatiello et al., 2001; Yigzaw et al.,
2001), suppressing either PHD1 or pVHL blunted the effect of
FGF-induced ERK kinase pathway due to increased SPRY2 pro-
tein level. In a subset of hepatocellular carcinoma, pVHL protein
levels were upregulated, and this led to decrease of SPRY2 pro-
tein that contributed to cancer progression (Lin et al., 2008).
However, about 70% renal cell carcinomas have defects in pVHL.
If the SPRY2 protein levels are upregulated in these tumors as
expected, it will be intriguing to ﬁnd out how this would impact
tumorigenesis.
β2-ADRENERGIC RECEPTOR
β2-adrenergic receptor (β2AR) is one of the G-protein-coupled
receptors (GPCRs). Besides generating second messengers, β2AR
plays an important role in control of cardiovascular functions
and apoptosis (Rockman et al., 2002; Table 1). Xie et al. (2009)
reported that hypoxia can stabilize β2AR protein by inhibiting
its ubiquitination. Further ﬁndings demonstrated that pVHL E3
ligase complex associated with β2AR protein in vivo, contribut-
ing to its ubiquitination and degradation. Mechanistically, prolyl
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hydroxylase PHD3 interactedwithβ2ARandmediated the hydrox-
ylation of the β2AR at proline residues 382 and 395, which primed
β2AR recognition by pVHL E3 ligase complex. β2AR accounts for
25–30% of total β-type adrenergic receptor in the human heart
and is the predominant form of the adrenergic receptor that exists
in some of smoothmuscles (Johnson, 1998; Rockman et al., 2002).
Interestingly, the β2AR protein is highly expressed in heart in vivo,
where PHD3 is also abundantly expressed (Xie et al., 2009). This
poses an apparent paradox, as PHD3 is the major enzyme that
modiﬁes β2AR for its degradation. It might be possible that the
PHD3-dependent destruction of β2AR is a regulated event and
only happens with external stimuli. Although it is unclear now, the
PHD3–β2AR–pVHL signaling axis might be operating in kidney
cancer and merits more investigation.
Myb-BINDING PROTEIN p160 (MYBBP1A)
Using an ICAT (isotope-coded afﬁnity tag) quantitative pro-
teomics technology, Lai et al. identiﬁed MYBBP1A as a novel
VHL substrate. MYBBP1A is a transcriptional regulator that can
activate or suppress gene transcription through interacting with
DNA-binding proteins (Tavner et al., 1998; Diaz et al., 2007;
Table 1). MYBBP1A was degraded by VHL in a prolyl hydroxyla-
tion dependent manner. Further research showed that MYBBP1A
proline 693 site as the potential hydroxylation site that might
trigger the interaction withVHL and subsequent degradation (Lai
et al., 2011). It remains largely unknown how MYBBP1A might
contribute to kidney cancer.
SUMMARY
Proline hydroxylation on HIFα proteins led to their recognition
by pVHL, followed by very efﬁcient ubiquitination and protea-
somal degradation. Without a functional VHL, HIF pathway is
strongly and constitutively active. So far this has been proved to be
the most signiﬁcant and clinically useful tumor suppressor func-
tion of pVHL. However, although proline hydroxylation on RPB1,
SPRY2, and β2AR also led to pVHL-dependent ubiquitination,
this did not automatically cause protein degradation as the ubiq-
uitin chain linkages on them might be different. It is also unclear
whether SPRY2 and β2AR are more abundant in VHL-defective
renal cancer cells and whether they contribute to tumor growth or
maintenance at all.
Interestingly, it is the active forms of EGFR and atypical PKC
that are ubiquitinated by pVHL and targeted for degradation. As
these kinases have pro-proliferating and anti-survival activities,
it is possible that their degradation is also important to pVHL’s
tumor suppressor function. It remains to be tested whether pro-
tein phosphorylations, in addition to proline hydroxylation, also
constitute a recognition signal for pVHL.
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